PIERIS AG
Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and other medical conditions with unmet medical needs. The company applies its proprietary Anticalin® technology to the drug development processes. Pieris Pharmaceuticals was founded in 2001 and is based in Freising, Bayern.
PIERIS AG
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2001-01-01
Address:
Hallbergmoos, Bayern, Germany
Country:
Germany
Website Url:
http://www.pieris-ag.com
Total Employee:
101+
Status:
Active
Contact:
+49 8161 1411400
Email Addresses:
[email protected]
Total Funding:
18.25 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Sectigo SSL Sectigo Domain SSL StackPath
Similar Organizations
Anteros Pharmaceuticals
Anteros Pharmaceuticals is a biotechnology company that develops drugs for fibrotic and other inflammatory diseases.
Fovea Pharmaceuticals
Fovea Pharmaceuticals is a French biopharmaceutical company that discovers and develops drugs for the treatment of ocular diseases.
Xenova
Xenova publicly quoted biotechnology company focused on the development of novel drugs to treat cancer and addiction.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Gilde IT Fund
Gilde IT Fund investment in Series B - Pieris AG
AAC Capital Partners
AAC Capital Partners investment in Series B - Pieris AG
BioM AG
BioM AG investment in Series B - Pieris AG
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Pieris AG
BayTech Venture Capital
BayTech Venture Capital investment in Series B - Pieris AG
Global Life Science Ventures
Global Life Science Ventures investment in Series B - Pieris AG
BayTech Venture Capital
BayTech Venture Capital investment in Series A - Pieris AG
TransConnect
TransConnect investment in Series A - Pieris AG
Global Life Science Ventures
Global Life Science Ventures investment in Series A - Pieris AG
BioM Venture Capital
BioM Venture Capital investment in Series A - Pieris AG
